-We tested the hypothesis that B-cell lymphomas arising in HCV-infected patients express BCRs specific to the virus.
Introduction
Survival of B cells requires the expression of BCR, as demonstrated in knockout mice 1, 2 and in some patients with non-X-linked agammaglobulinemia. Lymphoma B cells undergo somatic hypermutation in their V genes, which would be expected to generate protein loss variants. However, in the various lymphoma types, the BCR is retained 3 ,
suggesting importance for lymphoma cell survival. Yet, lymphomas' cognate antigens are not known. B-cell proliferative diseases such as mixed cryoglobulinemia (MC) and
Non-Hodgkin lymphoma (B-NHL) that arise in HCV-infected patients represent a special opportunity to study antigenic drive in lymphomagenesis. First, both MC and B-NHL use a restricted V gene repertoire shared by anti-HCV envelope antibodies 4, 5 . Second, elimination of HCV by anti-viral therapy in patients with these B-cell diseases has been associated with their regression 6 . Moreover, we previously identified an HCV-associated lymphoma whose BCR bound the HCV envelope protein E2 7 . Normal B cells aimed at eliminating HCV would be expected to bind the virus via two receptors, the cognate BCR and the viral entry receptor, CD81, which is a member of a costimulatory complex with CD19/CD21. Such B cells would receive dual stimulatory signals and might undergo unchecked proliferation during chronic HCV infection.
Here we tested this hypothesis by expressing BCRs from lymphomas of HCV-infected patients as soluble IgG and as membrane IgM. We included patients that had tumor regressions after anti-viral therapy 8 expecting that they would be more likely to express anti-HCV BCRs. We used several methods to test the reactivity of the rescued lymphoma BCRs with viral proteins and particles. However, we found no reactivity and therefore no evidence to support the hypothesis that viral antigens drive B-cell lymphomas.
Methods

Patients
Biopsies of patients with B-NHL and chronic HCV infection were collected at Stanford 
Expression of lymphoma idiotypes (Ids)
Amplified products were inserted into an IgG1 expression vector 9 , then expressed, as previously 4 . IgGs in the supernatant of transiently transfected COS-7 cells were quantitated by ELISA. Expression of the rescued V regions in A20 cells as membrane IgM was as previously 10 .
HCV proteins
Expression of E2 661 and J6E2 were as previously 7, 11 . HCV-E1E2 of various genotypes were encoded by pCR 3.1-UKN1B12.16, -UKN1B5.23, -UKN2A1.2, and -UKN2A2.4
12
.
The E1E2 sequences from these plasmids, and the E1E2 of the H77c strain (genotype 1a) were ligated into pCDM8 expression plasmids and transiently transfected into 293T
cells. An anti-HCV ELISA kit (DIAsource, Louvain-la-Neuve, Belgium) analyzed interaction of patient IgGs with core, NS3, NS5A and NS5B proteins.
Binding of rescued IgG and IgM
ELISA detecting binding to HCV-E2 was as previously 7 . Flow cytometry was used to detect rescue IgG binding to intracellular E1E2 in permeabilized 293T cells, and the binding of A20 cell surface IgM to soluble E2.
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Results and Discussion
The incidence of B-cell proliferative diseases, including MC and NHL is higher in HCVinfected patients than in non-infected individuals, especially in certain geographical areas, such as Italy 8, 13 . Moreover, the regression of B-cell diseases in response to successful anti-viral therapies implies a causative link between HCV infection and B-cell proliferative diseases 6, 8 . (Table 1) .
We sequenced the V region genes and expressed them as secreted human IgG1/κ in transfected cells. We then analyzed the reactivity of all rescued IgG1 with the soluble HCV E2 ectodomain, E2 661 (genotype 1a) 7 or J6E2 (genotype 2a) 11 . However, except for the anti-E2 mAb controls, none of the tested IgG1 reacted with E2 661 (Table 1) or with J6E2 ( Fig 1A) . Next, we tested all the rescued IgG1s with internal HCV antigens, which are included in a diagnostic kit; however, none reacted with core, NS3, NS5A and NS5B proteins ( Fig 1B) .
HCV is enveloped by two heterodimeric proteins, E1 and E2 14 . We tested the possibility that the rescued IgG1s recognize the heterodimer in its native membrane-bound form by using 293T cells transfected with constructs encoding full E1E2 polypeptides 12 . We specifically selected E1E2 of the HCV genotypes 1b and 2a matching the infected patients genotypes, as well as E1E2 derived from HCV isolate H77 of genotype 1a. The heterodimers were expressed intracellularly, as detected by flow cytometry using anti-E1
and anti-E2 mAb (Fig 1C, top panels) . However, none of the patients' rescued IgG1
showed reactivity (Fig 1C, bottom panels) . Chronic HCV infection is thought to have a causative role in MC, characterized by the benign proliferation of B cell secreting IgM with rheumatoid factor (RF) activity. Evidence also exists that implicate MC as the precursor to frank NHL. However, we did not find RF activity in any of the rescued IgG1s
(data not shown).
For
The VH-1 69 gene is also repetitively used in human mAbs that react with HIV 15 and with the influenza hemagglutinin (HA) protein 16 . Importantly, in a recent study germline VH-1 69 expressed as surface IgM reacted with HA, while soluble versions of the mAb were unreactive. It was proposed that clustering of surface BCR on a naïve B cell increases the avidity of the otherwise low-affinity germline BCR to HA to a level sufficient to trigger B-cell activation 17 . We therefore expressed the lymphoma Ids as human IgMs on A20, a mouse B cell line (Fig 1D top panel) and tested their reactivity with soluble E2 proteins.
However, only positive control cells expressing IgM with known anti-E2 reactivity showed binding to soluble E2 661 and J6E2 proteins (Fig 1D, middle and bottom panels, respectively). In addition, these cell-surface-expressed lymphoma Id IgMs did not bind HCV-core, or NS proteins (data not shown).
Lastly, we took a step further to explore whether lymphoma Ids interact with HCV proteins on an assembled virion. HCV produced in cell culture, HCVcc are associated with lipids 18,19 and may contain other antigens not studied in previous experiments.
However, incubation of HCVcc with A20 cells expressing surface lymphoma Id IgMs did not reduce their infectivity, whereas neutralizing anti-E2 mAbs (CBH-2 and CBH-5)
blocked infection (Fig 1E) . Non-neutralizing anti-E2 mAbs (CBH-4B, CBH-4G) expressed as cell surface IgMs (Fig 1E) , or as soluble CBH-4G mAb (data not shown), did not block infection.
This study tested the hypothesis that B cells aimed at eliminating the virus give rise to HCV-associated B-cell lymphomas. We included patients that responded to anti-viral therapy expecting them to be more likely to bind the virus. However, while confirming a restricted usage of VH-1 69 , we did not identify a single BCR that reacted with HCV (Table 1) , hence, no evidence to support the hypothesis. Table 1 For personal use only. For
